Ringworm Treatment in Children
For tinea corporis, tinea cruris, and tinea pedis in children, use topical antifungal agents (allylamines or azoles) for 2-4 weeks; for tinea capitis, oral therapy is mandatory—choose griseofulvin (15-20 mg/kg/day for 6-8 weeks) for Microsporum species or terbinafine (weight-based dosing for 2-4 weeks) for Trichophyton species. 1
Treatment by Site of Infection
Tinea Corporis, Cruris, and Pedis
These superficial infections typically respond to topical therapy alone:
- Topical allylamines (terbinafine, naftifine) or azoles (clotrimazole, miconazole, ketoconazole) applied twice daily for 2-4 weeks 2, 3
- Allylamines may offer slightly higher cure rates and shorter treatment courses due to their fungicidal action versus the fungistatic azoles 2
Reserve oral therapy for:
- Extensive disease
- Failed topical treatment
- Immunocompromised patients
- Hair follicle involvement 3
Critical pitfall: Avoid combination antifungal-corticosteroid products—these can worsen infection, promote resistance, and mask the true extent of disease 3. While one study showed potential benefit in atopic children with bacterial superinfection 4, this represents a narrow exception and should not guide general practice.
Tinea Capitis
Oral therapy is absolutely required—topical treatment alone does not achieve clinical or mycological cure 1. The scalp and hair shaft require systemic penetration.
Species-Directed Treatment Algorithm:
For Trichophyton species (T. tonsurans, T. violaceum, T. soudanense):
- First-line: Terbinafine 1
- <20 kg: 62.5 mg daily for 2-4 weeks
- 20-40 kg: 125 mg daily for 2-4 weeks
40 kg: 250 mg daily for 2-4 weeks
- Terbinafine shows superior efficacy for T. tonsurans specifically (52.1% vs 35.4% cure with griseofulvin; RR 1.47) 5
For Microsporum species (M. canis, M. audouinii):
- First-line: Griseofulvin 1
- <50 kg: 15-20 mg/kg/day for 6-8 weeks
50 kg: 1 g/day for 6-8 weeks
- Take with fatty food to enhance absorption 1
- Griseofulvin demonstrates better efficacy than terbinafine for Microsporum (50.9% vs 34.7% cure; RR 0.68) 5
Why this species distinction matters: Terbinafine is not excreted in sweat or sebum of prepubertal children and cannot effectively reach scalp surface arthroconidia in Microsporum infections. The minimum inhibitory concentration for terbinafine against M. canis often exceeds achievable hair concentrations 1.
When to Start Treatment:
Begin therapy immediately if you see:
- Kerion (inflammatory, boggy mass)
- Cardinal signs: scaling + lymphadenopathy + alopecia 1
These clinical features strongly predict tinea capitis and waiting 2-4 weeks for culture results increases transmission risk 1.
Treatment Failure Management:
First, consider:
- Non-compliance
- Suboptimal drug absorption
- Reinfection 1
If clinical improvement but positive mycology: Continue current therapy 2-4 weeks longer 1
If no clinical improvement: Switch to second-line itraconazole (5 mg/kg/day for 2-4 weeks or 50-100 mg/day for 4 weeks) 1
For refractory cases: Consider fluconazole or voriconazole in exceptional circumstances 1
Critical Additional Measures for Tinea Capitis
Family screening and treatment: For T. tonsurans cases, screen all household members and close contacts—over 50% may be infected, often asymptomatically. Treat all positive cases to prevent reinfection 1
Adjunctive topical therapy: Use antifungal shampoos (ketoconazole 2%, selenium sulfide 1%, or povidone-iodine) to reduce spore transmission, though these alone won't cure the infection 1
School attendance: Children on appropriate systemic therapy can attend school—exclusion is impractical and unnecessary 1
Treatment endpoint: Mycological cure, not just clinical improvement. Continue treatment until repeat cultures are negative 1
Safety Profile
All recommended agents show favorable safety in children:
- Terbinafine and griseofulvin have similar adverse event rates (9.2% vs 8.3%), predominantly mild GI disturbances and rashes 5
- Severe adverse events are rare (0.6% for both) 5
- Griseofulvin remains the only licensed treatment for tinea capitis in UK children, though terbinafine is widely used off-label 1
Avoid ketoconazole: Withdrawn in UK/Europe due to hepatotoxicity risk 1